Becton Dickinson on Monday said it plans to sell its Clontech business unit, putting on the sales block one of the most recognized brand assets in the molecular biology tools market.

The Franklin Lakes, NJ-based BD said it has retained Goldman Sachs to manage the deal and plans to take a $125 million pre-tax charge contingent upon completion of any sale of Clontech, a company acquired for $201 million in 1999. Clontech has 220 employees.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.